Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) announced collaborations with three academic institutions: MUSC Foundation for Research Development, Stanford University, and the University of Pittsburgh. These partnerships aim to translate innovative research into therapies for genetic diseases and cancers. BridgeBio's CEO, Neil Kumar, emphasized the significance of these collaborations in accelerating the development of life-changing medicines. The company has previously partnered with 23 institutions, showcasing its commitment to advancing patient treatment options.
On June 1, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 47,963 shares to 21 new employees under the 2019 Inducement Equity Plan. This action is compliant with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. BridgeBio is dedicated to developing medicines for genetic diseases and cancers, with over 30 programs in its pipeline. Founded in 2015, the company focuses on rapid advancements in genetic medicine to benefit patients.
BridgeBio Pharma (Nasdaq: BBIO) announced that the FDA granted Fast Track designation to encaleret for treating autosomal dominant hypocalcemia (ADH1). This rare genetic condition affects approximately 12,000 people in the U.S., causing severe calcium regulation issues. Current treatments are insufficient. Promising early results from a Phase 2b study show 100% normalization of blood and urine calcium in participants. This designation may expedite development and approval of encaleret, potentially the first therapy specifically for ADH1.
BridgeBio Pharma and Helsinn announced the FDA's approval of TRUSELTIQ (infigratinib) for previously-treated patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion. This marked BridgeBio's first oncology product approved by the FDA and the second overall this year. In clinical trials, TRUSELTIQ demonstrated a objective response rate of 23% and a median duration of response of 5 months. The companies will co-commercialize TRUSELTIQ in the U.S., sharing profits and losses equally.
On May 4, 2021, BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the granting of restricted stock units for 70,949 shares to 27 new employees. This decision was made by the compensation committee under the company's 2019 Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The Plan aims to incentivize new hires effectively. Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and cancers, with over 30 programs in various clinical stages.
BridgeBio Pharma (Nasdaq: BBIO) announced FDA Fast Track designation for BBP-631, a gene therapy for congenital adrenal hyperplasia (CAH). This designation aims to expedite the development of treatments addressing significant unmet medical needs. CAH affects over 75,000 cases in the U.S. and Europe. The company also presented preclinical data supporting the safety and efficacy of BBP-631 at the ASGCT Annual Meeting. Initial clinical trials are anticipated to begin soon, with data expected in late 2021 or early 2022.
BridgeBio Pharma has achieved significant milestones, including FDA approval for NULIBRY™ (fosdenopterin) as the first treatment for molybdenum cofactor deficiency Type A. The company reported proof-of-concept data for encaleret in Autosomal Dominant Hypocalcemia Type 1. A collaboration with Helsinn Group aims to co-develop infigratinib in oncology, with potential earnings of up to $2.45 billion. The completion of Eidos Therapeutics acquisition and the issuance of $750 million in Convertible Senior Notes bolster financial stability, ending Q1 2021 with $1 billion in cash and securities.
BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC San Diego to translate research in genetically driven conditions into therapeutic applications, focused on oncology and neurology. The collaboration aims to identify promising research programs and potentially sponsor them for clinical investigation. This partnership is part of BridgeBio's commitment to develop life-changing medicines for patients, utilizing its developmental expertise alongside UC San Diego's research capabilities. BridgeBio currently has 20 partnerships with leading academic institutions.
BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC Davis to enhance research and development for genetic diseases and cancers. The collaboration aims to explore and assess potential research projects in genetic disorders and precision oncology. BridgeBio emphasizes its commitment to translating innovative research into effective treatments, leveraging its partnerships with various academic institutions. This alliance marks a strategic move to expand BridgeBio’s initiatives in developing therapies for genetically driven conditions, enhancing its portfolio of over 30 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with Roswell Park Comprehensive Cancer Center to develop investigational therapies for genetically driven cancers. This partnership marks a significant step in BridgeBio's efforts to advance cancer treatment, allowing for new research opportunities and accelerated clinical pathways. The collaboration is part of BridgeBio's broader strategy to engage with leading academic institutions to translate scientific discoveries into effective treatments efficiently.